Homocysteine levels and MTHFR polymorphisms in young patients with acute myocardial infarction: A case control study

Hellenic Journal of Cardiology

Volumn 53, Issue 3, 2012, Pages 189-194

  Eftychiou, Christos ^a   Antoniades, Loizos ^a   Makri, Loukia ^b   Koumas, Laura ^c   Costeas, Paul A ^c   Kyriakou, Eleni ^d   Nicolaides, Evagoras ^a   Papadogiannis, Dimitrios ^e  

^a Nicosia General Hospital   (Greece)

^b Statistical Service of Cyprus   (Greece)

^c Molecular Hematology and Immunogenetics Center   (Greece)

^d NICOSIA GENERAL HOSPITAL   (Cyprus)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Atherosclerosis; Homocysteine; MTHFR; Myocardial infarction; Premature coronary artery disease

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ACUTE HEART INFARCTION; ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY RISK; DIABETES MELLITUS; DISEASE SEVERITY; DYSLIPIDEMIA; FAMILY HISTORY; GENERAL HOSPITAL; GENETIC POLYMORPHISM; HOMOZYGOSITY; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OBESITY; SMOKING; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; CASE-CONTROL STUDIES; CYPRUS; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RISK FACTORS; YOUNG ADULT;

EID: 84865847415     PISSN: 11099666     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. J Lab Clin Med. 1989; 114: 473-501.
2. Van Guelpen B, Hultdin J, Johansson I, et al. Plasma folate and total homocysteine levels are associated with the risk of myocardial infarction, independently of each other and of renal function. J Intern Med. 2009; 266: 182-195.
3. Christen WG, Ajani UA, Glynn RJ, Hennekens CH. Blood levels of homocysteine and increased risks of cardiovascular disease: causal or casual? Arch Intern Med. 2000; 160: 422-434.
4. Stein JH, McBride PE. Hyperhomocysteinemia and atherosclerotic vascular disease: pathophysiology, screening, and treatment. off. Arch Intern Med. 1998; 158: 1301-1306.
5. Sadeghian S, Fallahi F, Salarifar M, et al. Homocysteine, vitamin B12 and folate levels in premature coronary artery disease. BMC Cardiovasc Disord. 2006; 6: 38.
6. Puri A, Gupta OK, Dwivedi RN, Bharadwaj RP, Narain VS, Singh S. Homocysteine and lipid levels in young patients with coronary artery disease. J Assoc Physicians India. 2003; 51: 681-685.
7. Nikfardjam M, Graf S, Hornykewycz S, et al. Homocysteine plasma levels in young patients with coronary artery disease. Relation to history of acute myocardial infarction and anatomical extent of disease. Thromb Res. 2001; 103 Suppl 1: S35-S39.
8. Schwartz SM, Siscovick DS, Malinow MR, et al. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation. 1997; 96: 412-417.
9. Antoniades C, Antonopoulos AS, Tousoulis D, Stefanadis C. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. Eur Heart J. 2009; 30: 6-15.
10. Speidl WS, Nikfardjam M, Niessner A, et al. Mild hyperhomocysteinemia is associated with a decreased fibrinolytic activity in patients after ST-elevation myocardial infarction. Thromb Res. 2007; 119: 331-336.
11. Yeter E, Ozdemir L, Keleş T. Association of elevated plasma homocysteine levels with impaired ST-segment resolution after fibrinolytic therapy in acute ST-elevation myocardial in farction. Coron Artery Dis. 2008; 19: 163-166.
12. D'Angelo A, Coppola A, Madonna P, et al. The role of vitamin B12 in fasting hyperhomocysteinemia and its interaction with the homozygous C677T mutation of the methylenetetrahydrofolate reductase (MTHFR) gene. A case-control study of patients with early-onset thrombotic events. Thromb Haemost. 2000; 83: 563-570.
13. Gaustadnes M, Rüdiger N, Rasmussen K, Ingerslev J. Intermediate and severe hyperhomocysteinemia with thrombosis: a study of genetic determinants. Thromb Haemost. 2000; 83: 554-558.
14. Bazzano LA, He J, Muntner P, Vupputuri S, Whelton PK. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med. 2003; 138: 891-897.
15. Kang SS, Wong PW, Susmano A, Sora J, Norusis M, Ruggie N. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet. 1991; 48: 536-545.
16. Pintó X, Vilaseca MA, Garcia-Giralt N, et al. Homocysteine and the MTHFR 677C→T allele in premature coronary artery disease. Case control and family studies. Eur J Clin Invest. 2001 Jan; 31: 24-30.
17. Verhoeff BJ, Trip MD, Prins MH, Kastelein JJ, Reitsma PH. The effect of a common methylenetetrahydrofolate reductase mutation on levels of homocysteine, folate, vitamin B12 and on the risk of premature atherosclerosis. Atherosclerosis. 1998; 141: 161-166.
18. Genest JJ, McNamara JR, Upson B, et al. Prevalence of familial hyperhomocyst(e)inemia in men with premature coronary artery disease. Arterioscler Thromb. 1991; 11: 1129-1136.
19. Lewis SJ, Ebrahim S, Smith GD. Meta-analysis of MTHFR 677C→T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ. 2005; 331: 1053.
20. Chua S, Wu CJ, Chang HW, et al. Impact of elevated plasma total homocysteine concentration on coronary atherosclerosis in Chinese patients with acute myocardial infarction undergoing primary coronary intervention. Int Heart J. 2005; 46: 181-193.
21. Panayiotou A, Nicolaides A, Griffin M, et al. Serum total homocysteine, folate, 5,10-methylenetetrahydrofolate reductase (MTHFR) 677C→T genotype and subclinical atherosclerosis. Expert Opin Ther Targets. 2009; 13: 1-11.
22. de Jong SC, Stehouwer CD, van den Berg M, Vischer UM, Rauwerda JA, Emeis JJ. Endothelial marker proteins in hyperhomocysteinemia. Thromb Haemost. 1997; 78: 1332-1337.
23. Al-Obaidi MK, Philippou H, Stubbs PJ, et al. Relationships between homocysteine, factor VIIa, and thrombin generation in acute coronary syndromes. Circulation. 2000; 101: 372-377.
24. Matetzky S, Freimark D, Ben-Ami S, et al. Association of elevated homocysteine levels with a higher risk of recurrent coronary events and mortality in patients with acute myocardial infarction. Arch Intern Med. 2003; 163: 1933-1937.
25. Shojaie M, Naghshvar F, Izadi HR, Eshraghian A, Pourahmad M. Homocysteine level in Iranian patients with premature acute myocardial infarction. Chin Med J. 2009; 122: 1952-1954.
26. Barter PJ, Rye KA. Homocysteine and cardiovascular disease: is HDL the link? Circ Res. 2006; 99: 565-566.
27. Liao D, Tan H, Hui R, et al. Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I Protein synthesis and enhancing HDL cholesterol clearance. Circ Res. 2006; 99: 598-606.
28. Mikael LG, Genest J, Rozen R. Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease. Circ Res. 2006; 98: 564-571.
29. Bønaa KH, Njølstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006; 354: 1578-1588.
30. Lonn E, Yusuf S, Arnold MJ et al; Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006; 354: 1567-1577.
31. Clarke R, Halsey J, Lewington S et al; B-Vitamin Treatment Trialists' Collaboration. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med. 2010; 170: 1622-1631.
32. Ebbing M, Bleie, Ueland PM, et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA. 2008; 300: 795-804.
33. Martí-Carvajal AJ, Solà I, Lathyris D, Salanti G. Homocysteine lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2009 Oct 7; (4): CD006612.
34. Løland KH, Bleie O, Blix AJ, et al. Effect of homocysteinelowering B vitamin treatment on angiographic progression of coronary artery disease: a Western Norway B Vitamin Intervention Trial (WENBIT) substudy. Am J Cardiol. 2010; 105: 1577-1584.
35. Miller ER 3rd, Juraschek S, Pastor-Barriuso R, Bazzano LA, Appel LJ, Guallar E. Meta-analysis of folic acid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocysteine levels. Am J Cardiol. 2010; 106: 517-527.
36. Bazzano LA. Folic acid supplementation and cardiovascular disease: the state of the art. Am J Med Sci. 2009; 338: 48-49.
37. Clarke R, Halsey J, Lewington S, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med. 2010; 170: 1622-1631.
38. Papageorgiou N, Tousoulis D, Antoniades C, Giolis A, Briasoulis A, Stefanadis C. The impact of statin administration in acute coronary syndromes. Hellenic J Cardiol. 2010; 51: 250-261.